直肠癌全程新辅助治疗中短程放疗与长程放化疗的多中心早期结局与毒性分析
该回顾性多中心分析纳入2015至2024年接受全程新辅助治疗(TNT)的295例局部晚期直肠癌(LARC)患者,比较短程放疗(SCRT)与长程放化疗(LCRT)的早期结局。LCRT组完全缓解(CR)率和非手术治疗(NOM)率更高,但急性≥3级毒性未见显著差异;复发率两组相近。
要点
- LCRT与更高的CR(aOR 3.11)和NOM(aOR 4.40)几率相关。
- LCRT与急性毒性、慢性毒性、术后并发症及复发无显著关联。
- SCRT组急性≥3级毒性发生率为20.5%,LCRT组为36.3%。
核心结论
- 在TNT背景下,LCRT与更高的CR率和NOM率相关,但是否应优先于SCRT用于计划NOM仍需随机试验回答。
研究设计与样本
- 回顾性多中心分析(DRKS00033000),纳入2015至2024年接受TNT的LARC患者295例,中位年龄62岁,男性210例(71.2%)。
主要发现
- CR在SCRT组为46例(37.4%),LCRT组为96例(55.8%)。
- 急性≥3级毒性在SCRT组为24/117例(20.5%),LCRT组为62/171例(36.3%)。
- 中位随访SCRT组19.4个月、LCRT组19.6个月,复发分别为23/116例(19.8%)和30/155例(19.4%)。
- 多因素回归显示LCRT与CR(aOR 3.11;95%CI 1.37-7.07)和NOM(aOR 4.40;95%CI 1.46-13.21)几率增加相关。
- LCRT与急性毒性(aOR 0.90;95%CI 0.40-2.02)、慢性毒性(aOR 1.16;95%CI 0.48-2.78)、术后并发症(aOR 0.89;95%CI 0.62-1.28)及复发(aOR 0.81;95%CI 0.31-2.16)无显著关联。
临床怎么用
- 对于计划行NOM的LARC患者,LCRT可能提高CR和NOM机会,但需权衡急性毒性风险并个体化选择。
局限性
- 回顾性设计可能引入选择偏倚,随访时间较短,结论需随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Total neoadjuvant therapy (TNT) improves local control and complete response (CR) rates in locally advanced rectal cancer (LARC). CR is associated with favorable local tumor control, allowing non-operative management (NOM). However, it remains unclear whether short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCRT) is preferable within TNT. METHODS: LARC patients undergoing TNT between 2015 and 2024 were included in this retrospective multicenter analysis (DRKS00033000). The primary endpoint was CR. Secondary endpoints comprised NOM rates, toxicity, and tumor control. Multivariable logistic regression modelling was used to assess the influence of LCRT. RESULTS: Of 295 included patients with a median age at diagnosis of 62 (Q1-Q3: 54-68) years and 210 (71.2 %) men, 172 (58.3 %) underwent LCRT. CR was achieved in 46 (37.4 %) SCRT and 96 (55.8 %) LCRT patients. Acute toxicity grade ≥ 3 occurred in 24 (20.5 %) of 117 SCRT and in 62 (36.3 %) of 171 LCRT patients. Within a median follow-up of 19.4 months (SCRT) and 19.6 months (LCRT), 23 (19.8 %) of 116 and 30 (19.4 %) of 155 patients experienced recurrence, respectively. Regression modelling revealed an increased likelihood for CR (adjusted odds ratio: 3.11; 95 % confidence interval: 1.37-7.07) and NOM (4.40; 1.46-13.21) with LCRT, whereas no significant associations of LCRT with acute toxicity (0.90; 0.40-2.02), chronic toxicity (1.16; 0.48-2.78), postoperative complications (0.89; 0.62-1.28) or recurrence (0.81; 0.31-2.16) were observed. CONCLUSION: LCRT was associated with higher CR and NOM rates. Whether it might be preferred over SCRT for intended NOM remains a relevant question to be answered by ongoing randomized trials.
引用
- Wurschi G, Kesselmeier M, Schneider M, et al. Short-course radiotherapy versus long-course chemoradiotherapy in total neoadjuvant therapy of rectal cancer - A multicenter analysis of early outcomes and toxicity. Radiother Oncol. 2025. PMID: 41077142. doi:10.1016/j.radonc.2025.111194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。